10-Q: Syros Pharmaceuticals Reports Q3 2024 Results, Provides Update on Tamibarotene Clinical Trial

Syros Pharmaceuticals reported its third quarter 2024 financial results and provided an update on its ongoing clinical trial for tamibarotene.

Summary

• Syros Pharmaceuticals reported a net loss of $6.4 million for the third quarter of 2024, compared to a net loss of $40.1 million for the same period in 2023.
• The company's research and development expenses decreased to $20.5 million in Q3 2024 from $28.3 million in Q3 2023, primarily due to restructuring efforts.
• General and administrative expenses also decreased to $5.7 million in Q3 2024 from $7.8 million in Q3 2023.
• Syros did not recognize any revenue in Q3 2024, compared to $3.8 million in Q3 2023 from a collaboration agreement that has since been terminated.
• The company's cash and cash equivalents stood at $58.3 million as of September 30, 2024.
• Syros expects to report pivotal complete response data from the SELECT-MDS-1 trial in mid-November 2024.
• The company completed enrollment of 190 patients for the primary endpoint analysis of the SELECT-MDS-1 trial in the first quarter of 2024.
• Syros discontinued enrollment in the SELECT-AML-1 Phase 2 clinical trial based on an interim analysis.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While the company has reduced its losses and completed enrollment for a key trial, it faces significant financial challenges, including the need for additional funding and substantial doubt about its ability to continue as a going concern. The lack of revenue and discontinuation of a clinical trial are also negative factors.

Positives

• The company's net loss significantly decreased year-over-year, indicating improved financial performance.
• Research and development expenses were reduced by 27% due to restructuring efforts.
• The company completed enrollment for the primary endpoint analysis of the SELECT-MDS-1 trial.
• Syros has a clear timeline for reporting pivotal data from the SELECT-MDS-1 trial.

Negatives

• Syros did not generate any revenue in Q3 2024, compared to $3.8 million in Q3 2023.
• The company discontinued enrollment in the SELECT-AML-1 Phase 2 clinical trial.
• The company has an accumulated deficit of $756.2 million.
• There is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date of this report.

Risks

• The company's future viability is dependent on its ability to raise additional capital.
• Failure to satisfy the primary endpoint for the SELECT-MDS-1 trial or obtain FDA approval for tamibarotene by May 31, 2026, would constitute events of default under the Loan Agreement.
• The company faces substantial competition in the development and commercialization of treatments for myelodysplastic syndrome and acute myeloid leukemia.
• The company is dependent on third-party collaborators for the development and commercialization of a diagnostic test for use with tamibarotene.
• The company has incurred significant net operating losses since its inception and expects to continue to do so for the foreseeable future.

Future Outlook

The company expects to report pivotal complete response data from the SELECT-MDS-1 trial in mid-November 2024 and believes its current cash will fund operations into the third quarter of 2025. The company will need to raise additional capital to continue operations beyond that point.

Management Comments

• Management plans to pursue additional funding through equity or debt financings, business development transactions, and reducing cash expenditures.
• Management has assessed that there is substantial doubt about the company's ability to continue as a going concern for a period of at least 12 months from the issuance date of this report.

Industry Context

The company is operating in a competitive biopharmaceutical landscape, facing competition from major pharmaceutical and biotechnology companies developing treatments for hematologic malignancies. The company is specifically targeting the myelodysplastic syndrome market, which has seen recent drug approvals and ongoing clinical development by competitors.

Comparison to Industry Standards

• Syros's reduction in operating expenses aligns with industry trends of cost management, especially for companies in the clinical development stage.
• The company's focus on a specific genomic subset of patients (RARA overexpression) is a strategy used by other companies to target niche markets and improve clinical trial outcomes.
• The company's cash runway into the third quarter of 2025 is relatively short compared to some peers, highlighting the need for additional funding.
• The company's reliance on third-party collaborators for diagnostic tests is a common practice in the industry, but also introduces risks related to those collaborations.
• The company's decision to discontinue the SELECT-AML-1 trial is a common practice in the industry when interim data does not support further development.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees may be affected by potential further restructuring or layoffs if the company's financial situation does not improve.
• Patients may benefit from the potential approval of tamibarotene, but the company's financial instability could impact the drug's availability.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company expects to report pivotal complete response data from the SELECT-MDS-1 trial in mid-November 2024.
• The company will continue to seek additional funding to support its operations.
• The company will continue to develop and validate a laboratory-developed test for RARA overexpression.

Key Dates

Keywords

Syros Pharmaceuticals, Tamibarotene, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Clinical Trial, SELECT-MDS-1, RARA overexpression, Financial Results, Biopharmaceutical, Hematologic Malignancies